FDA Updates SMA Treatment Dosing - Summary - MDSpire

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

  • By

  • Kathryn Wighton

  • March 30, 2026

  • 2 min

Share

Objective:

To announce the FDA's approval of a higher-dose regimen of nusinersen for spinal muscular atrophy treatment.

Key Findings:
  • High-dose regimen showed statistically significant improvement in motor function in treatment-naïve infants compared to untreated groups.
  • Safety profile consistent with lower-dose regimen; common adverse events included pneumonia and malnutrition.
  • Monitoring for bleeding complications and kidney damage is recommended.
Interpretation:

The higher-dose nusinersen regimen offers enhanced efficacy while maintaining a similar safety profile, providing a promising option for SMA patients.

Limitations:
  • The study primarily focused on treatment-naïve infants; further data may be needed for broader patient populations.
  • Potential long-term effects of higher dosing are not fully established.
Conclusion:

The updated dosing regimen for nusinersen is expected to improve treatment outcomes for spinal muscular atrophy patients and will soon be available in the US.

Original Source(s)

FDA Updates SMA Treatment Dosing

  • by Kathryn Wighton

  • March 30, 2026

Related Content

Could Digital Twins Forecast Forensic Risk?

Researchers outline a proposed three-level framework spanning patient monitoring, ward operations, and forensic system planning.

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

Sex Disparities May Persist in CF Despite Modulators

Review findings suggested female patients with cystic fibrosis may continue to experience worse pulmonary outcomes despite highly effective modulator therapy